drugset / Trial / NCT01975441

Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

NCT01975441 ↗

Phase 2 Completed 182 enrolled University Hospitals Cleveland Medical Center
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given to treat this infection. The three drugs used together are called albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC). The usual treatment in Papua New Guinea (PNG) for lymphatic filariasis are DEC and ALB. A combination of these 3 drugs has not been previously used to treat LF.

Timeline

Start
2014-05
Primary completion
2017-12
Completion
2018-06

Outcome

Met primary endpoint

paper was superior to the two-drug regimen administered once and noninferior to the two-drug regimen administered once a year for 3 years. PMID 30403937 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Albendazole Small molecule 400 mg —
Subject Diethylcarbamazine Small molecule 6 mg/kg —
Subject Ivermectin Small molecule 200 ug/kg —

Indications